Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
79.4M
-
Number of holders
-
109
-
Total 13F shares, excl. options
-
31.5M
-
Shares change
-
+662K
-
Total reported value, excl. options
-
$914M
-
Value change
-
+$20.1M
-
Put/Call ratio
-
8
-
Number of buys
-
50
-
Number of sells
-
-40
-
Price
-
$29.01
Significant Holders of Akero Therapeutics, Inc. - COMMON STOCK (AKRO) as of Q1 2021
127 filings reported holding AKRO - Akero Therapeutics, Inc. - COMMON STOCK as of Q1 2021.
Akero Therapeutics, Inc. - COMMON STOCK (AKRO) has 109 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 31.5M shares
of 79.4M outstanding shares and own 39.69% of the company stock.
Largest 10 shareholders include ATP Life Science Ventures, L.P. (5.83M shares), JANUS HENDERSON GROUP PLC (3.48M shares), Redmile Group, LLC (2.51M shares), ALKEON CAPITAL MANAGEMENT LLC (2.5M shares), venBio Partners LLC (2.44M shares), HILLHOUSE CAPITAL ADVISORS, LTD. (1.66M shares), WELLINGTON MANAGEMENT GROUP LLP (1.54M shares), BlackRock Inc. (1.46M shares), VANGUARD GROUP INC (986K shares), and STATE STREET CORP (940K shares).
This table shows the top 109 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.